Holen Sie sich die Stockscreener-App
8.30
3.23%
0.26
Handel nachbörslich:
8.34
0.04
+0.48%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.04
Offen:
$8.07
24-Stunden-Volumen:
1.32M
Relative Volume:
0.47
Marktkapitalisierung:
$379.12M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-10.00
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
+7.24%
1M Leistung:
+8.64%
6M Leistung:
-46.62%
1J Leistung:
+111.46%
1-Tages-Spanne:
$7.91
$8.60
1-Wochen-Bereich:
$7.545
$9.43
52-Wochen-Spanne:
$3.79
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
8.30 | 357.21M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Capricor - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Capricor Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
Best data tools to analyze Capricor Therapeutics Inc. stockWeekly Trend Report & AI Driven Stock Price Forecasts - Newser
Lawsuit Alert: Investors who lost money with shares of Capricor - openPR.com
CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit - PR Newswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - FinancialContent
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. - GlobeNewswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Capricor Therapeutics: Q2 2025 Financial and Strategic Update - TipRanks
Capricor Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - GlobeNewswire Inc.
Capricor: Q2 Earnings Snapshot - San Antonio Express-News
Earnings call transcript: Capricor Therapeutics Q2 2025 sees widened loss, stock dips - Investing.com
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - MarketScreener
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,162 Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Custom watchlist performance reports with Capricor Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
Analyzing drawdowns of Capricor Therapeutics Inc. with statistical toolsTrade Safety Matrix for Conservative Traders - Newser
What earnings revisions data tells us about Capricor Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
What does recent volatility data suggest for Capricor Therapeutics Inc.Long-Term Trend Tracking and Signal Summary - Newser
Why Capricor Therapeutics Inc. is moving todayVolume Spike Detection for Early Breakouts - Newser
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
Capricor stock rises on FDA meeting for rejected drug (CAPR) - Seeking Alpha
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Capricor schedules FDA meeting on Duchenne therapy, delays earnings By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA | CAPR Stock News - GuruFocus
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire
Capricor's DMD Treatment Reaches Critical FDA Milestone: Type A Meeting to Discuss BLA Path - Stock Titan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional scanner results for Capricor Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
What to expect from Capricor Therapeutics Inc. in the next 30 daysPredictive Model for Intraday Swing Forecast - Newser
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm - FinancialContent
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - ACCESS Newswire
Capricor Therapeutics Q2 Earnings: Latest Updates on DMD Drug Deramiocel Coming August 13 - Stock Titan
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):